HighTower Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

HighTower Advisors’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,507	Closed	-$214K	–	3630
2022 Q1	$214K	Buy	+12,507	New	+$185K	﹤0.01%	2800
2016 Q2	–	Sell	-10,913	Closed	-$462K	–	2070
2016 Q1	$462K	Sell	10,913 -7,238	-40%	-$369K	﹤0.01%	1412
2015 Q4	$1.42M	Buy	18,151 +8,788	+94%	+$508K	0.02%	779
2015 Q3	$374K	Buy	9,363 +667	+8%	+$35.3K	0.01%	1347
2015 Q2	$453K	Buy	8,696 +1,173	+16%	+$58.4K	0.01%	1046
2015 Q1	$350K	Buy	+7,523	New	+$391K	0.01%	1187

Other funds holding ISEE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HighTower Advisors's ISEE Position: Q2 2022 in Review

HighTower Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2022, closing a stake of 12,507 shares — an estimated $214K sold.

HighTower Advisors first reported a position in ISEE in Q1 2015 and held it in 6 quarters. The position peaked at $1.42M in Q4 2015. 184 funds tracked by Wall St. Rank hold ISEE as of Q2 2022.

HighTower Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
HighTower Advisors sold 12,507 IVERIC bio, Inc. Common Stock shares in Q2 2022, an estimated $214K.
HighTower Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q1 2015 and held it in 6 quarters.
HighTower Advisors's IVERIC bio, Inc. Common Stock position peaked at $1.42M in Q4 2015.
184 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2022.

Based on HighTower Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.